Chronic Disease And CancerCondition

Digoxin randomized trial in rheumatic heart disease

April 4, 2026Harriette Van Spall, MD MPH

Harriette Van Spall highlights an ACC26 randomized trial claiming digoxin is effective, cheap, and reduces a composite of all-cause death or worsening heart failure in rheumatic heart disease, calling the 18 percent risk reduction huge.

Digoxin is effective, cheap, & ⬇️ composite ACD or WHF in rheumatic heart disease, which affects 54.8 million ppl in world
An 18% risk reduction is HUGE for a pragmatic investigator initiated RCT
Harriette Van Spall, MD MPH
heart failureRCTglobal health

See what experts are saying right now

This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.

← Back to Healthcare